Atara Biotherapeutics vs Molecular Partners
ATRA and MOLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRA and MOLN compare
Atara Biotherapeutics grew revenue faster over the last twelve months (−97.4% versus −100% for Molecular Partners).
Atara Biotherapeutics scores higher on the StockData Score (7 against 1 for Molecular Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRA | MOLN |
|---|---|---|
| Size and price | ||
| Market cap | $82.6M | – |
| Share price | $8.23 | $3.09 |
| Change, 1 year | −33.1% | −27.3% |
| Change, 5 years | −98.2% | −70.4% |
| Beta (5Y) | 1.65 | 0.90 |
| Employees | 14 | 34 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 20.8× | – |
| Growth | ||
| Revenue growth (TTM) | −97.4% (better) | −100% |
| Net income growth (TTM) | −162% | – |
| Profitability | ||
| Operating margin | −344% | – |
| Net margin | −369% | – |
| Financial health | ||
| Interest coverage | – | −11.5× |
| Current ratio | 1.72 | 7.27 (better) |
| Altman Z-score | −153.99 | – |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Buyback yield | −10.4% | – |
| Shareholder yield | −10.4% | – |
| Ownership | ||
| Held by institutions | 44.5% | 8.9% |
| Held by insiders | 55.5% | 0.00% |
| Insider net buying, 12 months | $2.0M | – |
| Short interest, % of float | 6.6% | – |
Go deeper
- ATRA stock overview
- ATRA income statement
- ATRA valuation and score
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.